Biophagy
Private Company
Funding information not available
Overview
Biophagy is a private, preclinical-stage biotech founded in 2016, pioneering a novel approach to treating neurodegenerative diseases and aging-related conditions by modulating the cellular autophagy process. The company operates a dual business model, combining proprietary drug development for high unmet medical needs with a direct-to-consumer wellness product, CellWatch™. Led by a team of seasoned pharmaceutical entrepreneurs and scientists, Biophagy is positioned at the intersection of cutting-edge biology and therapeutic development, though it faces significant risks inherent to novel drug discovery and a competitive landscape.
Technology Platform
Platform for discovering and developing therapeutics that modulate the cellular autophagy pathway, coupled with a diagnostic system (CellWatch™) to measure autophagy function.
Opportunities
Risk Factors
Competitive Landscape
Competition is intense, including large pharma (e.g., AbbVie, Novartis) and biotechs (e.g., Calico, Unity Biotechnology) exploring aging biology, as well as numerous companies targeting proteinopathies in neurodegeneration. Biophagy's focus on autophagy as a primary lever is a key differentiator but remains unproven.